Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Mar;8(1):e001828.
doi: 10.1136/rmdopen-2021-001828.

Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial

Catherine Beauvais  1 , Françoise Fayet  2 , Alexandra Rousseau  3 , Christelle Sordet  4 , Sophie Pouplin  5 , Yves Maugars  6   7 , Rose Marie Poilverd  8 , Carine Savel  2 , Véronique Ségard  4 , Béatrice Godon  9 , Christian L'amour  10 , Aleth Perdriger  11 , Fabienne Brin  12 , Patricia Peyrard  13 , Fabienne Chalier  14 , Béatrice Pallot-Prades  13 , Sophie Tuffet  8 , Isabelle Griffoul  15 , Laure Gossec  16   17
Affiliations
Randomized Controlled Trial

Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial

Catherine Beauvais et al. RMD Open. 2022 Mar.

Abstract

Objective: To evaluate the effect of a nurse-led patient education on safety skills of patients with inflammatory arthritis treated with biologic disease-modifying antirheumatic drugs (bDMARDs).

Methods: This is a multicentre, open-labelled, randomised controlled trial comparing an intervention group (face-to-face education by a nurse at baseline and 3 months later) with a control group (usual care) at the introduction of a first subcutaneous bDMARD. The primary outcome was score on the BioSecure questionnaire at 6 months (0-100 scale), a validated questionnaire assessing competencies in dealing with fever, infections, vaccination and daily situations. The secondary outcomes were disease activity, coping, psychological well-being, beliefs about medication, self-efficacy and severe infection rate.

Results: 129 patients with rheumatoid arthritis and spondyloarthritis were enrolled in nine rheumatology departments; 122 completed the study; 127 were analysed; and 64 received the intervention (mean duration: 65 min at baseline and 44 min at 3 months). The primary outcome was met: the BioSecure score was 81.2±13.1 and 75.6±13.0 in the education and usual care groups (difference: +6.2, 95% CI 1.3 to 11.1, p=0.015), demonstrating higher safety skills in the education group. Exploratory analyses showed better skills regarding infections, greater willingness for vaccinations and greater adherence-related behaviours in the education group. Coping was significantly more improved by education; other secondary outcomes were improved in both groups, with no difference.

Conclusions: Educating patients was effective in promoting patient behaviours for preventing adverse events with bDMARDs. An education session delivered to patients starting a first bDMARD can be useful to help them self-manage safety issues.

Trial registration number: NCT02855320.

Keywords: arthritis; biological therapy; nursing; patient care team.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CB reports research grants from BMS, Fresenius Kabi, Lilly and Mylan, and was an occasional speaker for BMS, AbbVie, MSD, Mylan, Pfizer, Roche, Sanofi and UCB. LG reports research grants from Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz and Sanofi, and consulting fees from AbbVie, Amgen, BMS, Biogen, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis and UCB. CSo reports occasional consulting fees from AbbVie, UCB, Lilly, Nordic, GSK, Roche Chugaï and BMS.

Figures

Figure 1
Figure 1
CONSORT 2010 flow diagram. aError regarding inclusion criteria. bDMARD, biologic disease-modifying antirheumatic drug; CONSORT, Consolidated Standards of Reporting Trials; ITT, intention-to-treat; PP, per protocol.
See this image and copyright information in PMC

References

    1. Smolen JS, Landewé R, Bijlsma J, et al. . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77. 10.1136/annrheumdis-2016-210715 - DOI - PubMed
    1. Daien C, Hua C, Gaujoux-Viala C, et al. . Update of French Society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine 2019;86:135–50. 10.1016/j.jbspin.2018.10.002 - DOI - PubMed
    1. van der Heijde D, Ramiro S, Landewé R, et al. . 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91. 10.1136/annrheumdis-2016-210770 - DOI - PubMed
    1. Wendling D, Lukas C, Prati C, et al. . 2018 update of French Society for rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. Joint Bone Spine 2018;85:275–84. 10.1016/j.jbspin.2018.01.006 - DOI - PubMed
    1. Singh JA, Cameron C, Noorbaloochi S, et al. . Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. The Lancet 2015;386:258–65. 10.1016/S0140-6736(14)61704-9 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data